Saturday Mar 1
Dechra Pharmaceuticals's "Buy" Rating Reaffirmed at FinnCap
's stock had its "buy" rating reiterated by FinnCap in a research note issued on Tuesday, Analyst Ratings.Net reports.
Fringe-rated credits in demand
The blatant hunger among investors for yield and diversification is creating pristine issuance conditions for fringe investment-grade rated companies, some of which are only just out of bankruptcy, helping them plant their flag in the US debt markets.
Panmure Gordon Reiterates "Buy" Rating for Dechra Pharmaceuticals
's stock had its "buy" rating reiterated by equities research analysts at Panmure Gordon in a research note issued to investors on Tuesday, American Banking and Market News reports.
Dechra Pharmaceuticals Upgraded by Nplus1 Brewin to "Buy"
The firm currently has a GBX 785 price objective on the stock, up from their previous price objective of GBX 740 .
Delphi Corporation Announces Pricing of Senior Notes Offering
The offering was upsized to $700 million from the previously announced amount of $500 million.
Press release distribution, EDGAR filing, XBRL, regulatory filings
The MyNature Grow a... )--Research and Markets has announced the addition of the "Concise Analysis of the International Switchgears Ma... )--Delphi Corporation , a subsidiary of Delphi Automotive PLC , announced today that it intends to offer, subject to market ... )--Agiliance announced that Cyber Defense Magazine has named its RiskVisionTM ... (more)
Delphi to Present at Barclays Industrial Select Conference on February 19
A simultaneous audio/video webcast of the presentation will be available on the Delphi Investor Relations website at investor.delphi.com/ .
Dechra Pharmaceuticals Given Hold Rating at Oriel Securities Ltd
's stock had its "hold" rating reiterated by research analysts at Oriel Securities Ltd in a report released on Tuesday, AnalystRatingsNetwork reports.